# Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

> **NCT06104423** · PHASE4 · COMPLETED · sponsor: **Menarini International Operations Luxembourg SA** · enrollment: 266 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Nebivolol 5 mg
- **DRUG:** Ramipril 2.5/5/10 mg

## Key facts

- **NCT ID:** NCT06104423
- **Lead sponsor:** Menarini International Operations Luxembourg SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-02
- **Primary completion:** 2024-02-19
- **Final completion:** 2024-02-19
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06104423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06104423, "Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06104423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*